Nonarmored GCC-Targeting CAR T-cell Therapy Demonstrates Significant Efficacy in Patients with Advanced Colorectal Cancer.
Clin Cancer ResOct 1, 2026
Clinical ResearchOncology (Medical)
Qianyu Zhang, Lin Lin, Wei Wang et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase I clinical trial evaluated the safety and preliminary efficacy of nonarmored GCC-targeted CAR T-cell therapy in 24 heavily pretreated metastatic colorectal cancer patients. The study found an objective response rate of 33% and a disease control rate of 63%, indicating promising antitumor activity despite significant toxicity.
Key findings
- 33% objective response rate and 63% disease control rate observed in patients.
- All patients experienced grade 3 or higher hematologic toxicity.
- 75% of patients developed manageable cytokine release syndrome.
- Median overall survival was 190 days.
Why it matters
The study highlights the potential of GCC-targeted CAR T-cell therapy as a novel treatment option for patients with advanced colorectal cancer, particularly those who have exhausted standard therapies. Understanding its efficacy and safety profile is crucial for future clinical applications.